Statistics notes. Treatment allocation in controlled trials: why randomise? - PubMed (original) (raw)

Review

Statistics notes. Treatment allocation in controlled trials: why randomise?

D G Altman et al. BMJ. 1999.

No abstract available

PubMed Disclaimer

Comment in

• Is recruitment more difficult with a placebo arm in RCTs? Methodological issues will have affected results.
  Forbes L, Chinn S, Figueroa-Muñoz J, Seed P. Forbes L, et al. BMJ. 1999 Sep 25;319(7213):853-4. doi: 10.1136/bmj.319.7213.853b. BMJ. 1999. PMID: 10496847 Free PMC article. No abstract available.

Similar articles

• Statistics notes: Concealing treatment allocation in randomised trials.
  Altman DG, Schulz KF. Altman DG, et al. BMJ. 2001 Aug 25;323(7310):446-7. doi: 10.1136/bmj.323.7310.446. BMJ. 2001. PMID: 11520850 Free PMC article. Review. No abstract available.
• Tools & techniques methodology and statistics: randomisation in clinical trials.
  Lenzen M, van Domburg R, Hoeks S, Kardys I, Boersma E. Lenzen M, et al. EuroIntervention. 2013 Jul;9(3):410-1. doi: 10.4244/EIJV9I3A65. EuroIntervention. 2013. PMID: 23872656 No abstract available.
• How to randomise.
  Altman DG, Bland JM. Altman DG, et al. BMJ. 1999 Sep 11;319(7211):703-4. doi: 10.1136/bmj.319.7211.703. BMJ. 1999. PMID: 10480833 Free PMC article. Review. No abstract available.
• Treatment allocation in clinical trials.
  Webert KE. Webert KE. Transfusion. 2007 Dec;47(12):2187-8. doi: 10.1111/j.1537-2995.2007.01445.x. Epub 2007 Aug 21. Transfusion. 2007. PMID: 17714423 No abstract available.
• Randomization. Part 3: allocation concealment and randomization implementation.
  Pandis N. Pandis N. Am J Orthod Dentofacial Orthop. 2012 Jan;141(1):126-8. doi: 10.1016/j.ajodo.2011.09.003. Am J Orthod Dentofacial Orthop. 2012. PMID: 22196195 No abstract available.

Cited by

• Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study.
  Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G. Grana C, et al. Br J Cancer. 2002 Jan 21;86(2):207-12. doi: 10.1038/sj.bjc.6600047. Br J Cancer. 2002. PMID: 11870507 Free PMC article. Clinical Trial.
• CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.
  Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. Zhao N, et al. Clin Cancer Res. 2022 Jul 15;28(14):3066-3075. doi: 10.1158/1078-0432.CCR-21-3858. Clin Cancer Res. 2022. PMID: 35604681 Free PMC article.
• A roadmap to using randomization in clinical trials.
  Berger VW, Bour LJ, Carter K, Chipman JJ, Everett CC, Heussen N, Hewitt C, Hilgers RD, Luo YA, Renteria J, Ryeznik Y, Sverdlov O, Uschner D; Randomization Innovative Design Scientific Working Group. Berger VW, et al. BMC Med Res Methodol. 2021 Aug 16;21(1):168. doi: 10.1186/s12874-021-01303-z. BMC Med Res Methodol. 2021. PMID: 34399696 Free PMC article. Clinical Trial.
• Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
  Li J, Qiu X, Guo W, Yan B, Zhang S. Li J, et al. Med Oncol. 2015 Oct;32(10):238. doi: 10.1007/s12032-015-0684-x. Epub 2015 Sep 2. Med Oncol. 2015. PMID: 26330362 Clinical Trial.
• Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method.
  Rogers JR, Hripcsak G, Cheung YK, Weng C. Rogers JR, et al. J Biomed Inform. 2021 Jul;119:103822. doi: 10.1016/j.jbi.2021.103822. Epub 2021 May 25. J Biomed Inform. 2021. PMID: 34044156 Free PMC article.

References

1. 1. Altman DG. Randomisation. BMJ. 1991;302:1481–1482. - PMC - PubMed
2. 1. Sacks H, Chalmers TC, Smith H. Randomized versus historical controls for clinical trials. Am J Med. 1982;72:233–240. - PubMed
3. 1. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet. 1980;i:339–340. - PubMed
4. 1. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet. 1991;338:131–137. - PubMed
5. 1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;2:769–782. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central